Company

Pyxis Oncology, Inc.

Public · PYXS

Pyxis Oncology is a biopharmaceutical company developing antibody-drug conjugates (ADCs) and immunotherapies to treat difficult-to-treat cancers. The company focuses on clinical assets designed to target tumor cells and overcome immune suppression. Led by an experienced management team, Pyxis advances innovative cancer therapies aimed at improving patient outcomes.

Pyxis Oncology, Inc. is a publicly traded company. It trades under the ticker PYXS. Leadership tracked by CEOInsider includes Thomas Civik (CEO).

www.pyxisoncology.com ↗LinkedIn ↗

Leadership

Current

Thomas Civik

CEO

Recent developments

AI summary of recent coverage

Recent coverage has focused on Pyxis Oncology's announcement of positive updated Phase 1 trial data for its head and neck cancer drug candidate, which showed tumor response rates and survival metrics ahead of a planned larger trial, prompting mixed market reactions including analyst price target increases alongside stock volatility. The company also announced a leadership change, naming Thomas Civik as CEO and Chairman. Analyst commentary has reflected divergent views, with some flagging safety concerns while others upgraded price targets on the strength of the clinical results.

Summarized from the headlines in the sidebar; see each source for the full story.